Table 2.
Results of MTT assays at intermediate concentrations
| MET 1 cells | Absorbance | P value vs. combination therapy |
|---|---|---|
| No inhibitor | 1.64±0.03 | <0.001 |
| +120nM erlotinib | 1.44±0.07 | 0.004 |
| +150nM PPP | 1.36±0.06 | 0.061 |
| +120nM erlotinib+150nM PPP | 1.27±0.04 | n/a |
| +500nM erlotinib | 1.24±0.03 | 0.007 |
| +150nM PPP | 1.39±0.03 | 0.001 |
| +500nM erlotinib+150nM PPP | 1.09±0.02 | n/a |
| MET4 cells | ||
| No inhibitor | 1.70±0.03 | <0.001 |
| +120nM erlotinib | 1.52±0.02 | <0.001 |
| +120nM PPP | 1.34±0.06 | 0.015 |
| +120nM erlotinib+120nM PPP | 1.17±0.06 | n/a |
| SCC12 cells | ||
| No inhibitor | 1.02±0.02 | 0.001 |
| +120nM erlotinib | 0.94±0.03 | 0.030 |
| +240nM PPP | 0.95±0.01 | 0.003 |
| +120nM erlotinib+240nM PPP | 0.82±0.02 | n/a |
| SCC13 cells | ||
| No inhibitor | 2.41±0.02 | 0.001 |
| +120nM erlotinib | 2.21±0.02 | 0.012 |
| +60nM PPP | 2.21±0.03 | 0.018 |
| +120nM erlotinib+60nM PPP | 2.00±0.04 | n/a |